Fluoxetine treatment of patients with major depressive disorder who failed initial treatment with sertraline
| Autor: | Jeffrey T. Apter, Michael E. Thase, Rosalinda G. Tepner, Sharon L. Blomgren, Martin A. Birkett |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Adult
Male medicine.medical_specialty Internal medicine Fluoxetine Sertraline medicine Ambulatory Care Humans Prospective Studies Treatment Failure Psychiatry Prospective cohort study Adverse effect Depression (differential diagnoses) Psychiatric Status Rating Scales Depressive Disorder Hamilton Rating Scale for Depression medicine.disease Psychiatry and Mental health 1-Naphthylamine Treatment Outcome Research Design Major depressive disorder Female Reuptake inhibitor Psychology Selective Serotonin Reuptake Inhibitors medicine.drug |
| Zdroj: | The Journal of clinical psychiatry. 58(1) |
| ISSN: | 0160-6689 |
| Popis: | Background This study was conducted to determine if patients with major depressive disorder who had previously failed treatment with one serotonin selective reuptake inhibitor (SSRI) would respond to a different SSRI. Method Adult outpatients (N = 106) with DSM-III-R major depressive disorder and a history of either intolerance (N = 34) or nonresponse (N = 72) to treatment with sertraline were treated with fluoxetine (mean dose = 37.2 mg/day) in a standardized, open-label, 6-week clinical trial. Outcome was assessed at each visit using the Hamilton Rating Scale for Depression (HAM-D), the Clinical Global Impressions (CGI-Improvement and CGI-Severity) scales, and the Patient's Global Improvement (PGI) scale. Results Ninety-one patients (86%) completed the study. Sixty-seven patients (63%) responded to fluoxetine (i.e., experienced > or = 50% reduction in HAM-D28 total score at endpoint versus baseline). In addition, clinically and statistically significant improvements were noted on all measures of depressive symptoms and global functioning. There was a nonsignificant trend for patients with a history of less vigorous sertraline trials to respond more favorably to fluoxetine. Fluoxetine therapy was generally well tolerated, and there were only slight differences in adverse events reported by patients who had been intolerant to sertraline versus those who were nonresponders. Conclusion These findings indicate that fluoxetine and sertraline, two widely used SSRIs, are not interchangeable. Patients who either have had trouble tolerating or have not responded to sertraline may do well on fluoxetine treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|